Maolin Yan

15PUBLICATIONS
22CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jun 23, 2026
Prognostic Value of the SEA Score in Double-Negative DCP/AFP Unresectable HCC with Triple Therapy.

|Jan 21, 2026
Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study.

Xiaoyun Zhang, Haozheng Cai, Wei Peng

|Oct 05, 2025
Transarterial chemoembolization plus atezolizumab and bevacizumab in patients with intermediate hepatocellular carcinoma: a single-arm, phase 2 trial.

Kang Wang, Jinkai Feng, Hongming Yu

|Jun 23, 2025
Long-term survival in advanced unresectable HCC treated with transcatheter arterial chemoembolization combined with lenvatinib and PD-1 inhibitors.

Zhen-Xin Zeng, Hua-Chun Song, Yi-Nan Li

|Jun 18, 2025
Prognostic Value of the SII-PNI Score in Unresectable HCC Treated with Transcatheter Arterial Chemoembolization Combined with Lenvatinib and PD-1 Inhibitors.

Shao-Ming Wei, Zhen-Xin Zeng, Rong-Jian Pan

|Apr 21, 2025
Combination Therapy of Transarterial Chemoembolization, Lenvatinib, and PD-1 Inhibitors Achieves Significant Tumor Response in Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Report.

Yangkai Fu, Junyi Wu, Jiayi Wu

Pageof 3

Frequent Collaborators

3 joint publications

Jiayi Wu

3 joint publications

Shuqun Cheng

1 joint publications

Li-Jun Xie

1 joint publications

Dan-Dan Ruan